The FDA has approved Rapiblyk (landiolol), an ultra-short-acting beta-blocker, for the short-term treatment of supraventricular tachycardia (SVT), including atrial...

The European Commission approved BeiGene‘s tislelizumab (TEVIMBRA), combined with chemotherapy, for first-line treatment of esophageal squamous cell carcinoma (ESCC)...

Acadia Pharmaceuticals has licensed SAN711, a first-in-class drug, from Saniona for global development and commercialization. The drug is targeted...

Arrowhead Pharmaceuticals announced its financial results for the 2024 fiscal year, highlighting the submission of its first New Drug...

Claudin 18.2, a protein typically found in tight junctions, has emerged as a promising therapeutic target for various cancers,...

Median Technologies, a developer of AI-powered medical imaging software, will present its latest advancements at the 2024 Radiological Society...

The global lung cancer therapy market, valued at $32.50 billion in 2023, is projected to reach $70.39 billion by...

Nutcracker Therapeutics, a biotechnology company specializing in RNA therapies, announced its participation in the 2024 Personalized Cancer Vaccine Summit,...

Lantern Pharma, through its subsidiary Starlight Therapeutics, revealed preclinical data and Phase 1b trial designs for LP-184 (STAR-001 for...

Exelixis announced that the FDA will discuss its supplemental New Drug Application for cabozantinib, intended to treat advanced pancreatic...